Roche Aktie

339,99 EUR +0,40 EUR +0,12 %

17:32:46

STU

340,00 EUR -5,00 EUR -1,45 %

17:34:49

HAML

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.274,53 Mrd. EUR

KGV20,28Div. Rendite2,99%

WKNA424UK

ISINCH1499059983

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

24.04.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

19.04.24GlobeNewswireFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

17.04.24GlobeNewswireRoche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

15.04.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

11.04.24GlobeNewswireRoche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

10.04.24PR NewswireRoche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

26.03.24GlobeNewswireRoche receives FDA approval for the first molecular test to screen for malaria in blood donors

12.03.24GlobeNewswireRoche Annual General Meeting 2024

12.03.24PR NewswireRoche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

05.03.24GlobeNewswireRoche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when add

25.02.24GlobeNewswireNew England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

16.02.24GlobeNewswireFDA approves Xolair as first and only medicine for children and adults with one or more food allergies

13.02.24PR NewswireRoche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

12.02.24PR NewswireRoche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

01.02.24GlobeNewswireNew long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

01.02.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

30.01.24PR NewswireRoche is awarded IDC Best in Future of Intelligence award for implementing data mesh strategy at scale with Immuta

16.01.24GlobeNewswireEuropean Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

03.01.24PR NewswireRemix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing

29.12.23GlobeNewswireRoche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

19.12.23GlobeNewswireFDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

19.12.23PR NewswireRoche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports

15.12.23GlobeNewswireRoche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices

11.12.23GlobeNewswireNew data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

09.12.23GlobeNewswireNew data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

08.12.23GlobeNewswireRoche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treat

08.12.23GlobeNewswireRoche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

05.12.23GlobeNewswireRoche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

04.12.23GlobeNewswireRoche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

27.11.23GlobeNewswireRoche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection

20.11.23PR NewswireRoche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges

16.11.23GlobeNewswireRoche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.